T2 Biosystems Stock Forecast, Price & News

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

Is T2 Biosystems a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" T2 Biosystems stock.
View analyst ratings for T2 Biosystems or view top-rated stocks.

How has T2 Biosystems' stock been impacted by Coronavirus?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTOO stock has increased by 19.9% and is now trading at $0.5934.
View which stocks have been most impacted by COVID-19.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for T2 Biosystems.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) announced its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($0.08) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.08). T2 Biosystems had a negative net margin of 162.84% and a negative trailing twelve-month return on equity of 1,278.55%. During the same period in the prior year, the business earned ($0.08) earnings per share.
View T2 Biosystems' earnings history.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $25 million-$27 million, compared to the consensus revenue estimate of $25.02 million.

What price target have analysts set for TTOO?

4 analysts have issued twelve-month target prices for T2 Biosystems' shares. Their forecasts range from $1.65 to $3.50. On average, they expect T2 Biosystems' share price to reach $2.91 in the next year. This suggests a possible upside of 390.8% from the stock's current price.
View analysts' price targets for T2 Biosystems or view top-rated stocks among Wall Street analysts.

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:

• John J. Sperzel, Chairman, President & Chief Executive Officer
• Alec Barclay, Chief Operations Officer
• John M. Sprague, Chief Financial Officer
• Roger Smith, Vice President-Science, Research & Development
• Sandy J. Estrada, Vice President-Medical Affairs

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems CEO John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among T2 Biosystems' employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of T2 Biosystems' key competitors?

Some companies that are related to T2 Biosystems include Tactile Systems Technology (TCMD), Beyond Air (XAIR), Assure (ARHH), AVITA Medical (RCEL), InfuSystem (INFU), ClearPoint Neuro (CLPT), Asensus Surgical (ASXC), PAVmed (PAVM), Westaim (WEDXF), Retractable Technologies (RVP), Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), DarioHealth (DRIO), NeuroPace (NPCE) and Apollo Endosurgery (APEN).
View all of TTOO's competitors.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.77%), Millennium Management LLC (0.98%), Geode Capital Management LLC (0.91%), Natixis (0.32%), Gagnon Securities LLC (0.31%) and GSA Capital Partners LLP (0.10%). Company insiders that own T2 Biosystems stock include Adrian M Jones, Alec Barclay, David B Elsbree, Goldman Sachs & Co Llc, John M Sprague, John Mcdonough, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Gagnon Securities LLC, Advisor Group Holdings Inc., Citadel Advisors LLC, BlackRock Inc., and HAP Trading LLC. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, John M Sprague, John Mcdonough, and Michael Terrence Gibbs.
View insider buying and selling activity for T2 Biosystems or view top insider-selling stocks.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including Natixis, GSA Capital Partners LLP, Welch & Forbes LLC, Franklin Resources Inc., Geode Capital Management LLC, Barclays PLC, Valeo Financial Advisors LLC, and Geneos Wealth Management Inc.. Company insiders that have bought T2 Biosystems stock in the last two years include Adrian M Jones, and Goldman Sachs & Co Llc.
View insider buying and selling activity for T2 Biosystems or or view top insider-buying stocks.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.59.

How much money does T2 Biosystems make?

T2 Biosystems has a market capitalization of $98.49 million and generates $18.13 million in revenue each year. The medical equipment provider earns $-46.80 million in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does T2 Biosystems have?

T2 Biosystems employs 148 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

Where are T2 Biosystems' headquarters?

T2 Biosystems is headquartered at 101 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at (781) 761-4646, via email at [email protected], or via fax at 781-357-3080.